Polarean Imaging (GB:POLX) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Polarean Imaging PLC, a medical device company specializing in MRI lung function imaging, announces its year-end results for 2023, along with the appointment of Christopher von Jako as the new CEO. The company has achieved significant milestones, including FDA approvals, strategic partnerships, and a successful fundraising round, securing its operations until at least Q1 2026. Polarean is focused on the commercialization of its FDA-approved XENOVIEW technology, with the aim to revolutionize pulmonary medicine.
For further insights into GB:POLX stock, check out TipRanks’ Stock Analysis page.